The MFN pricing approach, while politically attractive, raises complex questions about how to fairly and sustainably price ...
In light of the recent Congressional Budget Office report highlighting the impact of lower National Institutes of Health ...
In today’s Pharmaceutical Executive Daily, we cover the FDA’s creation of a new National Priority Voucher Program, the market ...
Galapagos announced plans to scale back on its cell therapy business, while the company pursues new transformational business ...
Sanofi's Tzield gains FDA's expedited review, promising rapid access to innovative treatment for type 1 diabetes and ...
Frontier Scientific Solutions, a contract service organization (CSO), and Air Transport Services Group, a provider of ...
The adoption of artificial intelligence (AI) has accelerated, yet its impact on R&D productivity remains underwhelming.
Pharmaceutical Executive: What impact will TrumpRx and other DTC programs have on drug availability? Jesse Mendelsohn: To be ...
Armstrong highlights Artax’s focus on moving into other autoimmune diseases like rheumatoid arthritis and atopic dermatitis. An explanation for the shift from oral drugs with many side effects to ...
Peptilogics Founder and CEO, Jonathan Steckbeck noted that advances in peptide design and safety have positioned the field to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback